GlassScriptPhysician profile
Peter J Schanen
NPI 1720491442
$4,182.34
in general payments reported to CMS, 2019-2025
24 companies · $952 in 2025
The $952 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $358 · 2022: $1,296 · 2023: $1,157 · 2024: $419 · 2025: $952.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,527.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $803.93 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $692.25 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $581.72 | 2022-2025 | |
| Antares Pharma, INC. | $527.49 | 2022-2023 | Xyosted, Tlando, Nocdurna |
| Astrazeneca Pharmaceuticals LP | $222.67 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Esperion Therapeutics, INC. | $142.62 | 2023-2025 | Nexletol |
| Inspire Medical Systems, INC. | $140.49 | 2022 | |
| Galderma Laboratories, L.P. | $137.69 | 2021-2022 | |
| Si-Bone, INC. | $126.24 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $101.91 | 2024-2025 | |
| Pfizer INC. | $101.50 | 2023-2025 | |
| Exact Sciences Corporation | $97.59 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Ibsa Pharma INC. | $88.76 | 2022-2025 | Flector, Licart, Tirosint |
| Tolmar, INC. | $79.38 | 2023-2025 | Jatenzo |
| Alk-Abello, INC | $59.94 | 2025 | Grastek, Ragwitek, Odactra |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acerus Pharmaceuticals Corporation | $52.51 | 2021-2022 | |
| Shield Therapeutics INC | $35.47 | 2025 | |
| Halozyme INC | $34.91 | 2023 | |
| Vertex Pharmaceuticals Incorporated | $31.37 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.64 | 2025 | Xifaxan |
| Dexcom, INC. | $28.49 | 2025 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $25.61 | 2022 | |
| Idorsia Pharmaceuticals US INC | $20.46 | 2024 | Quviviq |
| Avanir Pharmaceuticals, INC. | $19.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Schanen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.